Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Report Expects Drug MNCs To Favor China, India Partners

This article was originally published in PharmAsia News

Executive Summary

An international report suggests multinational drug makers prefer signing long-term manufacturing contracts with Asian counterparts, particularly in China and India. The Citigroup report said the trend would be to treat Asian companies as partners rather than suppliers or vendors of drugs. The report is based on an annual survey of pharmaceutical and biotechnology companies. The report noted China's WuXi PharmaTech and India's Nicholas Piramal appear to be the most likely companies sought out for those partnerships. Close behind, it named Dishman Pharmaceuticals & Chemicals and Jubilant Organosys, both of India. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts